Search
The Strep A Translation team aim to understand the epidemiology of Strep A infections in Australia and the world. Alongside this, they explore the implementation of endgame recommendations, health economics and new horizons.
Research
Improving primary prevention of acute rheumatic fever in Australia: consensus primary care priorities identified through an eDelphi processTo establish the priorities of primary care providers to improve assessment and treatment of skin sores and sore throats among Aboriginal and Torres Strait Islander people at risk of acute rheumatic fever (ARF) and rheumatic heart disease (RHD).
Research
Searching for a technology-driven acute rheumatic fever test: the START study protocolThe absence of a diagnostic test for acute rheumatic fever (ARF) is a major impediment in managing this serious childhood condition. ARF is an autoimmune condition triggered by infection with group A Streptococcus.
Research
Modelling study of the ability to diagnose acute rheumatic fever at different levels of the Ugandan healthcare systemTo determine the ability to accurately diagnose acute rheumatic fever given the resources available at three levels of the Ugandan healthcare system.
Research
Short- versus standard-course intravenous antibiotics for peri-prosthetic joint infections managed with debridement and implant retention: a randomised pilot trial using a desirability of outcome ranking (DOOR) endpointPeri-prosthetic joint infection (PJI) is a devastating complication of joint replacement surgery. Determining the optimal duration of intravenous (IV) antibiotics for PJI managed with debridement and implant retention (DAIR) is a research priority.
Research
Antimalarials for children with Plasmodium vivax infection: Current status, challenges, and research prioritiesThe aim of this narrative review is to summarise efficacy and pharmacokinetic data for Plasmodium vivax in children. The burden of P. vivax malaria in children continues to remain a significant public health issue, and the need for improved treatment regimens for this vulnerable population is critical.
Research
The economic and health burdens of diseases caused by group A Streptococcus in New ZealandIn preparation for the future arrival of a group A Streptococcus (GAS) vaccine, this study estimated the economic and health burdens of GAS diseases in New Zealand. The annual incidence of GAS diseases was based on extrapolation of the average number of primary healthcare episodes managed each year in general practices (2014-2016) and on the average number of hospitalizations occurring each year (2005-2014). Disease incidence was multiplied by the average cost of diagnosing and managing an episode of disease at each level of care to estimate the annual economic burden.
Research
Increasing incidence of invasive group A streptococcal disease in Western Australia, particularly among Indigenous peopleThe incidence of invasive GAS disease in WA increased between 2000 and 2018, particularly among Indigenous Australians. Mandatory notification of invasive GAS disease would therefore be appropriate. The social determinants of differences in incidence should be addressed, and other relevant host, pathogen, and health system factors investigated.
Research
Structured review of primary interventions to reduce group A streptococcal infections, acute rheumatic fever and rheumatic heart diseaseRheumatic heart disease (RHD) is a large, preventable, global public health burden. In New Zealand (NZ), acute rheumatic fever (ARF) and RHD rates are highest for Māori and Pacific children. This structured review explores the evidence for primary prevention interventions to diagnose and effectively treat group A Streptococcus (GAS) pharyngitis and skin infections to reduce rates of ARF and RHD.
Research
Coalition to Advance Vaccines Against Group A Streptococcus (CANVAS): A Trans-Tasman Initiative Against Rheumatic FeverInvestigators: Amy Baker, Jeffrey Cannon, Jonathan Carapetis, Katherine Gray, Yue Wu External collaborators: University of Auckland: Nikki Moreland,